1-Guanidino-2-methyl-propan-2-ol | 44838-96-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-Guanidino-2-methyl-propan-2-ol
• 英文别名: 1-(2-hydroxy-2-methylpropyl)guanidine；2-(2-hydroxy-2-methylpropyl)guanidine
• CAS: 44838-96-2
• 化学式: C₅H₁₃N₃O
• 分子量: 131.178
• InChiKey: DVMMEAUWUGXHMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  84.6
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (3Z)-1-cyclopropyl-4-(dimethylamino)-3-[2-(pyridin-4-ylamino)pyrimidin-4-yl]but-3-en-2-one 、 1-Guanidino-2-methyl-propan-2-ol 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以39%的产率得到1-((4'-(cyclopropylmethyl)-2-(pyridin-4-ylamino)-[4,5'-bipyrimidin]-2'-yl)amino)-2-methylpropan-2-ol
  参考文献：
  名称：

  [EN] BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS
  [FR] COMPOSÉS BI-HÉTÉROARYLES EN TANT QU'INHIBITEURS DE VPS34

  摘要：

  本发明涉及治疗由Vps34高活性特征的疾病或紊乱的新方法，以及作为Vps34抑制剂的化合物；特别是公式I的化合物或其药用盐，以及治疗与Vps34抑制相关的疾病、紊乱或综合症的方法，特别是高增殖性疾病。本发明还包括包括公式I化合物及其药用盐的药物组合物。

  公开号：

  WO2012085815A1
• 作为产物：
  描述：

  1-氨基-2-甲基-2-丙醇 、 S-甲基异硫脲硫酸盐 生成 1-Guanidino-2-methyl-propan-2-ol
  参考文献：
  名称：

  Syntheses of Aminoalkylguanidine Derivatives.

  摘要：

  N1-苄基-2-甲基-1,2-丙二胺（I）和 5-氨基-1,3-二苄基-5-甲基六氢嘧啶（II）的盐酸盐在加压催化氢化作用下发生脱苄基反应。由 I 得到的 2-甲基-1, 2-丙二胺（III）被衍生成单胍化合物。通过比较相关化合物的红外光谱，可以断定该化合物的结构为（2-氨基-2-甲基丙基）胍。从 II 中得到的 2-甲基-1，2，3-丙三胺、其起始原料 II 和其他乙二胺衍生物也在硫酸 S-甲基异硫脲的作用下被胍化。

  DOI：

  10.1248/cpb.15.936

文献信息

• [EN] BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS<br/>[FR] COMPOSÉS BI-HÉTÉROARYLES EN TANT QU'INHIBITEURS DE VPS34
  申请人：NOVARTIS AG

  公开号：WO2012085815A1

  公开（公告）日：2012-06-28

  The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.

  本发明涉及治疗由Vps34高活性特征的疾病或紊乱的新方法，以及作为Vps34抑制剂的化合物；特别是公式I的化合物或其药用盐，以及治疗与Vps34抑制相关的疾病、紊乱或综合症的方法，特别是高增殖性疾病。本发明还包括包括公式I化合物及其药用盐的药物组合物。
• BI-HETEROARYL COMPOUNDS AS VPS34 INHIBITORS
  申请人：Taracido Ivan Cornella

  公开号：US20140155402A1

  公开（公告）日：2014-06-05

  The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I: or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.

  本发明包括治疗由Vps34高活性所特征的疾病或障碍的新方法，以及作为Vps34抑制剂的化合物；特别是公式I的化合物：或其药学上可接受的盐，以及治疗与Vps34抑制相关的疾病、障碍或综合症的方法，特别是增殖过度性疾病的方法。本发明还包括包括公式I的化合物和其药学上可接受的盐的药物组合物。
• Bi-heteroaryl compounds as Vps34 inhibitors
  申请人：Taracido Ivan Cornella

  公开号：US08685993B2

  公开（公告）日：2014-04-01

  The present invention includes novel methods of treating a disease or disorder characterized by hyperactivity of Vps34, and compound as Vps34 inhibitors; particularly compounds of Formula I or a pharmaceutically acceptable salt thereof, as well as methods of treating a disease, disorder, or syndrome associated with Vps34 inhibition, particularly hyperproliferative diseases. The present invention also includes pharmaceutical compositions including compounds of formula I and pharmaceutically acceptable salts thereof.

  本发明包括治疗由Vps34过度活化引起的疾病或障碍的新方法，以及作为Vps34抑制剂的化合物；特别是公式I的化合物或其药学上可接受的盐，以及治疗与Vps34抑制相关的疾病、障碍或综合征的方法，特别是增殖过度性疾病。本发明还包括包括公式I的化合物及其药学上可接受的盐的制药组合物。
• Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy <i>in Vivo</i>
  作者：Ayako Honda、Edmund Harrington、Ivan Cornella-Taracido、Pascal Furet、Mark S. Knapp、Meir Glick、Ellen Triantafellow、William E. Dowdle、Dmitri Wiedershain、Wieslawa Maniara、Christine Moore、Peter M. Finan、Lawrence G. Hamann、Brant Firestone、Leon O. Murphy、Erin P. Keaney

  DOI：10.1021/acsmedchemlett.5b00335

  日期：2016.1.14

  Autophagy is a dynamic process that regulates lysosomal-dependent degradation of cellular components. Until recently the study of autophagy has been hampered by the lack of reliable pharmacological tools, but selective inhibitors are now available to modulate the PI 3-kinase VPS34, which is required for autophagy. Here we describe the discovery of potent and selective VPS34 inhibitors, their pharmacokinetic (PK) properties, and ability to inhibit autophagy in cellular and mouse models.
• Syntheses of Aminoalkylguanidine Derivatives.
  作者：Tadakazu Tsuji、Hiroko Momona、Takeo Ueda

  DOI：10.1248/cpb.15.936

  日期：——

  The hydrochlorides of N1-benzyl-2-methyl-1, 2-propanediamine (I) and 5-amino-1, 3-dibenzyl-5-methylhexahydropyrimidine (II) were debenzylated by the catalytic hydrogenation under pressure. 2-Methyl-1, 2-propanediamine (III) which obtained from I, was derived to monoguanidine compound. The structure of this compound was concluded to be (2-amino-2-methylpropyl) guanidine from the comparison of the infrared spectra of related compounds. 2-Methyl-1, 2, 3-propanetriamine obtained from II, its starting material II, and other ethylenediamine derivatives were also guanidilated by the action of S-methylisothiourea sulfate.

  N1-苄基-2-甲基-1,2-丙二胺（I）和 5-氨基-1,3-二苄基-5-甲基六氢嘧啶（II）的盐酸盐在加压催化氢化作用下发生脱苄基反应。由 I 得到的 2-甲基-1, 2-丙二胺（III）被衍生成单胍化合物。通过比较相关化合物的红外光谱，可以断定该化合物的结构为（2-氨基-2-甲基丙基）胍。从 II 中得到的 2-甲基-1，2，3-丙三胺、其起始原料 II 和其他乙二胺衍生物也在硫酸 S-甲基异硫脲的作用下被胍化。